Nan Chen

Nan Chen

Auto-generated profile, based on publicly available information

Nan Chen

Division of Cancer Care and Epidemiology, Queen’s University , Kingston, Ontario

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JVJoao Paulo Solar Vasconcelos
Joao Paulo Solar Vasconcelos
NCNan Chen
Nan Chen
ETEmma Titmuss
Emma Titmuss
DTDongsheng Tu
Dongsheng Tu
SBStephanie Y. Brule
Stephanie Y. Brule
JLJonathan M Loree
Jonathan M Loree
Purpose: Sidedness is prognostic and predictive of anti-EGFR efficacy in metastatic colorectal cancer (mCRC). Transverse colon has been historically excluded from several analyses of sidedness and the optimal division between left- and right-sided colorectal cancer is unclear. We investigated transverse colon primary tumor location as a biomarker in mCRC. Experimental Design: Pooled analysis of CCTG/AGITG CO.17 and CO.20 trials of cetuximab in chemotherapy-refractory mCRC. Outcomes of patients with RAS/BRAF wild-type (WT) mCRC from CO.17 and KRAS WT mCRC from CO.20 were analyzed according to location. Results: A total of 553 patients were analyzed, 32 (5.8%) with cancers from the transverse, 101 (18.3%) from right, and 420 from (75.9%) left colon. Transverse mCRC failed to reach significant benefit from cetuximab versus best supportive care (BSC) for overall survival [OS; median, 5.9 vs. 2.1 months; HR, 0.63; 95% confidence interval (CI), 0.28–1.42; P=0.26] and progression-free survival (PFS; median, 1.8 vs. 1.3 months; HR, 0.57; 95% CI, 0.26–1.28; P=0.16). Analyzing exclusively patients randomized to cetuximab, right-sided and transverse had comparable outcomes for OS (median, 5.6 vs. 5.9 months; HR, 0.82; 95% CI, 0.50–1.34; P=0.43) and PFS (median, 1.9 vs. 1.8 months; HR, 0.78; 95% CI, 0.49–1.26; P=0.31). Patients with left-sided mCRC had superior outcomes with cetuximab compared with transverse for OS (median, 9.7 vs. 5.9 months; HR, 0.42; 95% CI, 0.27–0.67; P=0.0002) and PFS (median, 3.8 vs. 1.8 months; HR, 0,49; 95% CI, 0.31–0.76; P=0.001). Location was not prognostic in patients treated with BSC alone. Conclusions: Transverse mCRC has comparable prognostic and predictive features with right-sided mCRC.

14 August 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
Bishal GyawaliBishal Gyawali
Bishal Gyawali
NCNan Chen
Nan Chen
DTDongsheng Tu
Dongsheng Tu
JPJoseph Pater
Joseph Pater
Background: The incidence and worsening of financial difficulty among patients with cancer participating in clinical trials and their relationship with mortality, quality of life, and toxicity outcomes have been understudied. The objective of this study was to understand the incidence of financial difficulty among Canadian patients participating in systemic therapy trials at baseline and after trial participation and to assess the relationship between financial difficulty and clinical outcomes. Methods: This retrospective cohort study included patients participating in 14 systemic therapy trials conducted by the Canadian Cancer Trials Group for adult patients with advanced cancer. Incidence of financial toxicity at baseline and after trial participation were measured using the European Organisation for Research and Treatment of Cancer QLQ Core Questionnaire. The association of financial difficulty with trial characteristics and patient outcomes (mortality, quality of life, and toxicity) was studied. Results: Overall, 2766 patients from 14 trials were included, of whom 37% had financial difficulty at baseline and 25% experienced worsening of financial difficulty after trial enrollment compared with their baseline status. Baseline financial difficulty but not the worsening of financial difficulty was associated with worse mortality outcomes. Worsening of financial difficulty was, however, associated with poor global quality of life outcomes and increased odds of clinical toxicities. Conclusions: Even in the setting of a public health system in Canada, one-third of patients experience financial difficulty, with one-quarter of them experiencing worsening of financial difficulty with trial participation, and both were related to worse patient outcomes. Targeted policy-level interventions are needed to understand and address the cause of financial difficulty in patients with cancer.


15 March 2024
Verified
Other
Open access
JVJoao Paulo Solar Vasconcelos
Joao Paulo Solar Vasconcelos
NCNan Chen
Nan Chen
ETEmma Titmuss
Emma Titmuss
DTDongsheng Tu
Dongsheng Tu
SBStephanie Y. Brule
Stephanie Y. Brule
JLJonathan M Loree
Jonathan M Loree
Purpose:Sidedness is prognostic and predictive of anti-EGFR efficacy in metastatic colorectal cancer (mCRC). Transverse colon has been historically excluded from several analyses of sidedness and the optimal division between left- and right-sided colorectal cancer is unclear. We investigated transverse colon primary tumor location as a biomarker in mCRC.Experimental Design:Pooled analysis of CCTG/AGITG CO.17 and CO.20 trials of cetuximab in chemotherapy-refractory mCRC. Outcomes of patients with RAS/BRAF wild-type (WT) mCRC from CO.17 and KRAS WT mCRC from CO.20 were analyzed according to location.Results:A total of 553 patients were analyzed, 32 (5.8%) with cancers from the transverse, 101 (18.3%) from right, and 420 from (75.9%) left colon. Transverse mCRC failed to reach significant benefit from cetuximab versus best supportive care (BSC) for overall survival [OS; median, 5.9 vs. 2.1 months; HR, 0.63; 95% confidence interval (CI), 0.28–1.42; P=0.26] and progression-free survival (PFS; median, 1.8 vs. 1.3 months; HR, 0.57; 95% CI, 0.26–1.28; P=0.16). Analyzing exclusively patients randomized to cetuximab, right-sided and transverse had comparable outcomes for OS (median, 5.6 vs. 5.9 months; HR, 0.82; 95% CI, 0.50–1.34; P=0.43) and PFS (median, 1.9 vs. 1.8 months; HR, 0.78; 95% CI, 0.49–1.26; P=0.31). Patients with left-sided mCRC had superior outcomes with cetuximab compared with transverse for OS (median, 9.7 vs. 5.9 months; HR, 0.42; 95% CI, 0.27–0.67; P=0.0002) and PFS (median, 3.8 vs. 1.8 months; HR, 0,49; 95% CI, 0.31–0.76; P=0.001). Location was not prognostic in patients treated with BSC alone.Conclusions:Transverse mCRC has comparable prognostic and predictive features with right-sided mCRC.

15 March 2024
Verified
Other
Open access
JVJoao Paulo Solar Vasconcelos
Joao Paulo Solar Vasconcelos
NCNan Chen
Nan Chen
ETEmma Titmuss
Emma Titmuss
DTDongsheng Tu
Dongsheng Tu
SBStephanie Y. Brule
Stephanie Y. Brule
JLJonathan M Loree
Jonathan M Loree
Purpose:Sidedness is prognostic and predictive of anti-EGFR efficacy in metastatic colorectal cancer (mCRC). Transverse colon has been historically excluded from several analyses of sidedness and the optimal division between left- and right-sided colorectal cancer is unclear. We investigated transverse colon primary tumor location as a biomarker in mCRC.Experimental Design:Pooled analysis of CCTG/AGITG CO.17 and CO.20 trials of cetuximab in chemotherapy-refractory mCRC. Outcomes of patients with RAS/BRAF wild-type (WT) mCRC from CO.17 and KRAS WT mCRC from CO.20 were analyzed according to location.Results:A total of 553 patients were analyzed, 32 (5.8%) with cancers from the transverse, 101 (18.3%) from right, and 420 from (75.9%) left colon. Transverse mCRC failed to reach significant benefit from cetuximab versus best supportive care (BSC) for overall survival [OS; median, 5.9 vs. 2.1 months; HR, 0.63; 95% confidence interval (CI), 0.28–1.42; P=0.26] and progression-free survival (PFS; median, 1.8 vs. 1.3 months; HR, 0.57; 95% CI, 0.26–1.28; P=0.16). Analyzing exclusively patients randomized to cetuximab, right-sided and transverse had comparable outcomes for OS (median, 5.6 vs. 5.9 months; HR, 0.82; 95% CI, 0.50–1.34; P=0.43) and PFS (median, 1.9 vs. 1.8 months; HR, 0.78; 95% CI, 0.49–1.26; P=0.31). Patients with left-sided mCRC had superior outcomes with cetuximab compared with transverse for OS (median, 9.7 vs. 5.9 months; HR, 0.42; 95% CI, 0.27–0.67; P=0.0002) and PFS (median, 3.8 vs. 1.8 months; HR, 0,49; 95% CI, 0.31–0.76; P=0.001). Location was not prognostic in patients treated with BSC alone.Conclusions:Transverse mCRC has comparable prognostic and predictive features with right-sided mCRC.